Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

NCT01935934 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

102

Enrollment

NIH

Sponsor class

Conditions

Endometrial Adenosquamous Carcinoma
Endometrial Clear Cell Adenocarcinoma
Endometrial Mixed Cell Adenocarcinoma
Endometrial Serous Adenocarcinoma
Metastatic Endometrioid Adenocarcinoma
Recurrent Malignant Uterine Corpus Neoplasm
Stage IV Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
Uterine Corpus Carcinosarcoma

Interventions

DRUG: Cabozantinib S-malate
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)